Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price vs HII: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HII's multiple
Needs HII P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · HII FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.27x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 81% equity / 19% debt
HII carries the larger enterprise value at $13.97B against $1.85B; HII trades on the lower EV / Revenue multiple (1.12x vs 2.13x); HRMY on the lower EV / EBITDA (7.27x vs 10.59x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
HUNTINGTON INGALLS INDUSTRIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
0.53x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
—
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
—
Total debt
Interest-bearing obligations outstanding
$163.66M
$2.70B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
GENERAL DYNAMICS CORP
HRMY vs GD
LOCKHEED MARTIN CORP
HRMY vs LMT
NORTHROP GRUMMAN CORP /DE/
HRMY vs NOC
TEXTRON INC
HRMY vs TXT
Howmet Aerospace Inc.
HRMY vs HWM
AXON ENTERPRISE, INC.
HRMY vs AXON
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
